Timothy Esq - Prometheus Biosciences G Sec
| RXDXDelisted Stock | USD 199.92 0.24 0.12% |
Insider
Timothy Esq is G Sec of Prometheus Biosciences
| Age | 44 |
| Phone | 858 684 1300 |
| Web | https://www.prometheusbiosciences.com |
Prometheus Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.2006) % which means that it has lost $0.2006 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.333) %, meaning that it created substantial loss on money invested by shareholders. Prometheus Biosciences' management efficiency ratios could be used to measure how well Prometheus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Prometheus Biosciences currently holds 14.76 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Prometheus Biosciences has a current ratio of 13.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Prometheus Biosciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Dr MBA | Blueprint Medicines Corp | 54 | |
| Quoc LeNguyen | 89bio Inc | 56 | |
| Narinderjeet MS | Arcellx | 52 | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Gloria Lin | Krystal Biotech | N/A | |
| Gina Mazzariello | Amylyx Pharmaceuticals | 53 | |
| Kate Aiken | Arcellx | N/A | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Tracey Esq | Blueprint Medicines Corp | 56 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Rakhi Kumar | Roivant Sciences | 44 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| MS MBA | Krystal Biotech | 59 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Justin Klee | Amylyx Pharmaceuticals | 33 | |
| Neeraj Teotia | Arcellx | 49 | |
| Eric Rojas | Stoke Therapeutics | N/A | |
| Christopher MD | Arcellx | 44 | |
Management Performance
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 |
Prometheus Biosciences Leadership Team
Elected by the shareholders, the Prometheus Biosciences' board of directors comprises two types of representatives: Prometheus Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prometheus. The board's role is to monitor Prometheus Biosciences' management team and ensure that shareholders' interests are well served. Prometheus Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prometheus Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allison MD, Chief Officer | ||
| Noel Kurdi, VP Communications | ||
| Timothy Esq, G Sec | ||
| Chris Doughty, Chief Officer | ||
| Mark McKenna, CEO Pres | ||
| Nori Ebersole, Chief Officer | ||
| Olivier Laurent, Chief RD | ||
| MBA MBA, Chief Officer | ||
| Mark Stenhouse, Chief Officer |
Prometheus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prometheus Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (40.65) % | |||
| Current Valuation | 4.39 B | |||
| Shares Outstanding | 47.81 M | |||
| Shares Owned By Insiders | 16.61 % | |||
| Shares Owned By Institutions | 81.01 % | |||
| Number Of Shares Shorted | 4.68 M | |||
| Price To Earning | (5.66) X | |||
| Price To Book | 19.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |